Alterity Therapeutics Company
Part of the Life Biosciences group of companies, Alterity is developing first-in-class therapies to treat neurodegenerative disease. Their lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
Technology:
Medical Devices
Industry:
Longevity
Headquarters:
United States
Founded Date:
1997
Employees Number:
11-50
Funding Status:
IPO
Estimated Revenue:
Less than $1M
Register and Claim Ownership